Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-09-26

FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie. The action updates the product labeling to reflect the approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mavyret (glecaprevir/pibrentasvir)

Snippet

SUPPL AP for MAVYRET (GLECAPREVIR AND PIBRENTASVIR)